Spots Global Cancer Trial Database for ABX Combined With Cisplatin Compared With Gemcitabine Combined With Cisplatin in NSCLC
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: ABX Combined With Cisplatin Compared With Gemcitabine Combined With Cisplatin in NSCLC
Official Title: ABX Combined With Cisplatin Compared With Gemcitabine Combined With Cisplatin in First Line Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer Stage II Randomized Controlled Trials
Study ID: NCT01810367
Conditions
Study Description
Brief Summary: Assess the PFS/ORR/OS of ABX Combined With Cisplatin Compared With Gemcitabine Combined With Cisplatin in first Treatment of NSCLC
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Cancer hospital Fudan University, Shanghai, Shanghai, China
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
